GSK says tests show Vir antibody drug works against Omicron

GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based COVID-19 therapy it is developing with U.S. partner Vir has indicated that the drug also works against the new Omicron variant.

Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)